Jazz Pharmaceuticals (JAZZ) Intangibles (2010 - 2026)

Jazz Pharmaceuticals' Intangibles history runs 17 years deep, the most recent figure standing at $4.2 billion for Q1 2026.

• In Q1 2026, Intangibles fell 10.9% year-over-year to $4.2 billion; the TTM figure through Mar 2026 stood at $4.2 billion (down 10.9% YoY), while the FY2025 annual figure was $4.4 billion, down 6.86% from the prior year.
• Intangibles was $4.2 billion for Q1 2026 at Jazz Pharmaceuticals, down from $4.4 billion in the prior quarter.
• In the past five years, Intangibles ranged from a high of $6.8 billion in Q1 2022 to a low of $752.5 million in Q4 2023.
• Historically, Intangibles has averaged $5.0 billion across 5 years, with a median of $5.1 billion in 2024.
• The sharpest annual moves came in 2022 and 2023: Intangibles surged 556939.4% in 2022, then sank 87.01% in 2023.
• A 5-year view of Intangibles shows it stood at $5.8 billion in 2022, then tumbled by 87.01% to $752.5 million in 2023, then surged by 531.99% to $4.8 billion in 2024, then slipped by 6.86% to $4.4 billion in 2025, then dropped by 5.1% to $4.2 billion in 2026.
• The last three Intangibles figures came in at $4.2 billion (Q1 2026), $4.4 billion (Q4 2025), and $4.6 billion (Q3 2025), per Business Quant data.